We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: hidradenitis suppurativa
MedXY News
EnglishTag

hidradenitis suppurativa

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa: Efficacy, Safety, and Economic Assessments
Clinical UpdatesbiologicsCost-Effectiveness

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa: Efficacy, Safety, and Economic Assessments

By MedXY|Aug 11, 2026

This review synthesizes current evidence on adalimumab, secukinumab, and bimekizumab for moderate-to-severe hidradenitis suppurativa, emphasizing clinical efficacy, safety, mechanistic insights, and cost-effectiveness across diverse health

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program
Clinical Updatesbimekizumab
clinical trials

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program

By MedXY|Mar 6, 2026

This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients

Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa
Allergy & Immunologyhidradenitis suppurativa

Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa

By MedXY|Mar 5, 2026

The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therap

Precision Dosing of Secukinumab in Hidradenitis Suppurativa: Insights from the SUNSHINE and SUNRISE Pooled Pharmacokinetic Analysis
Clinical Updatesbiologicshidradenitis suppurativa

Precision Dosing of Secukinumab in Hidradenitis Suppurativa: Insights from the SUNSHINE and SUNRISE Pooled Pharmacokinetic Analysis

By MedXY|Mar 5, 2026

This review synthesizes the 52-week pooled results from two Phase 3 trials, detailing the pharmacokinetics, safety, and biomarker responses of secukinumab in moderate-to-severe hidradenitis suppurativa.

Targeting CXCR1/2 Ligands: Eltrekibart Demonstrates Clinical Potential in Phase 2 Hidradenitis Suppurativa Trial
Dermatologydermatologyhidradenitis suppurativa

Targeting CXCR1/2 Ligands: Eltrekibart Demonstrates Clinical Potential in Phase 2 Hidradenitis Suppurativa Trial

By MedXY|Mar 5, 2026

A Phase 2 trial of eltrekibart, a novel monoclonal antibody targeting CXCR1/2 ligands, suggests high clinical efficacy in hidradenitis suppurativa. While frequentist analysis was neutral, Bayesian augmented models showed a 99.9% probability

Validating the Patient’s Voice in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Patient-Reported Outcome Measures
Clinical Updatesclinical outcomeshidradenitis suppurativa

Validating the Patient’s Voice in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Patient-Reported Outcome Measures

By MedXY|Mar 5, 2026

This systematic review and meta-analysis evaluates 15 HS-specific PROMs using the COSMIN framework, identifying 7 recommended instruments and highlighting the superior psychometric performance of HiSQOL-17 while uncovering significant gaps

Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking
Clinical UpdatesBMIhidradenitis suppurativa

Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking

By MedXY|Dec 24, 2025

Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemi

Standardizing How Clinicians See Hidradenitis Suppurativa: Key Consensus on Lesion Definitions and Investigator Guidance from a Modified Delphi Exercise
Dermatologyclinical trialsDelphi consensus

Standardizing How Clinicians See Hidradenitis Suppurativa: Key Consensus on Lesion Definitions and Investigator Guidance from a Modified Delphi Exercise

By MedXY|Nov 27, 2025

An international Delphi consensus produced standardized morphological definitions and practical guidance to improve investigator lesion assessment in hidradenitis suppurativa clinical trials, enhancing reliability and trial data quality.

Standardizing How Investigators Identify Hidradenitis Suppurativa Lesions: Key Findings from a Modified Delphi Consensus
Dermatologyclinical trialsDelphi consensus

Standardizing How Investigators Identify Hidradenitis Suppurativa Lesions: Key Findings from a Modified Delphi Consensus

By MedXY|Nov 27, 2025

A multidisciplinary Delphi panel produced consensus morphological definitions and practical guidance to standardize investigator lesion assessments in hidradenitis suppurativa (HS) clinical trials — improving reliability of endpoints such a

Comparative Efficacy and Safety of Treatments for Moderate to Severe Hidradenitis Suppurativa: Insights from a Living Network Meta-Analysis
Dermatologybiologicshidradenitis suppurativa

Comparative Efficacy and Safety of Treatments for Moderate to Severe Hidradenitis Suppurativa: Insights from a Living Network Meta-Analysis

By MedXY|Oct 27, 2025

This living systematic review and network meta-analysis evaluates efficacy, safety, and tolerability of medical treatments for moderate to severe hidradenitis suppurativa, highlighting top-performing agents and informing clinical decision-m

Risk of New-Onset and Recurrent Depression and Anxiety Among Patients With Hidradenitis Suppurativa
Dermatologyanxietydepression

Risk of New-Onset and Recurrent Depression and Anxiety Among Patients With Hidradenitis Suppurativa

By MedXY|Oct 6, 2025

Patients with hidradenitis suppurativa face a higher risk of first-time depression and anxiety, regardless of disease severity, highlighting the need for comprehensive psychiatric care.

Elevated Risk of Depression and Anxiety in Hidradenitis Suppurativa: Implications Beyond Disease Severity
Allergy & Immunologyanxietydepression

Elevated Risk of Depression and Anxiety in Hidradenitis Suppurativa: Implications Beyond Disease Severity

By MedXY|Oct 6, 2025

Patients with hidradenitis suppurativa face a significantly increased risk of new-onset depression and anxiety, independent of disease severity, highlighting the need for universal psychiatric assessment in this population.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities